Equities
  • Price (EUR)46.98
  • Today's Change0.46 / 0.99%
  • Shares traded1.46k
  • 1 Year change+9.13%
  • Beta0.7218
Data delayed at least 15 minutes, as of Jan 18 2021 17:46 GMT.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Announcements

    Key statistics

    On Monday, Novozymes A/S (NZM2b:DEU) closed at 46.98, -17.67% below its 52-week high of 57.06, set on Sep 14, 2020.
    52-week range
    Today
    34.06Mar 16 202057.06Sep 14 2020
    Markit short selling activity
    Low
    Med
    High
    Open47.13
    High47.36
    Low46.44
    Bid46.83
    Offer47.21
    Previous close46.52
    Average volume2.56k
    Shares outstanding231.26m
    Free float157.05m
    P/E (TTM)31.89
    Market cap80.69bn DKK
    EPS (TTM)10.94
    DKK
    Annual div (ADY)0.7027
    EUR
    Annual div yield (ADY)1.51%
    Div ex-dateFeb 27 2020
    Div pay-dateMar 02 2020
    Data delayed at least 15 minutes, as of Jan 18 2021 17:46 GMT.
    More ▼
    The Financial and Risk business of Thomson Reuters is now Refinitiv
    All markets data located on FT.com is subject to the FT Terms & Conditions
    All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
    Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.
    Markit Short Selling Activity © Markit. All rights reserved.
    Although Markit has made every effort to ensure this data is correct, nevertheless no guarantee is given to the accuracy or completeness. Any opinions or estimates expressed herein are those of Markit on the date of preparation and are subject to change without notice; however no such opinions or estimates constitute legal, investment or other advice. You must therefore seek independent legal, investment or other appropriate advice from a suitably qualified and/or authorised and regulated advisor prior to making any legal, investment or other decision. This is intended for information purposes only and is not intended as an offer or recommendation to buy, sell or otherwise deal in securities.